From: SARS-COV-2 vaccine responses in renal patient populations
Dialysis N = 260 | Transplant N = 209 | Autoimmune N = 223 | |
---|---|---|---|
Age (years) (median (range)) | 71 (20–95) | 57 (23–78) | 59 (19–88) |
Sex (male) (Number (%)) | 149 (63) | 108 (58) | 90 (47) |
Vaccine type (Number (%)) | |||
- Pfizer | 159 (61) | 140 (67) | 80 (36) |
- AstraZeneca | 92 (36) | 69 (33) | 138 (62) |
- Unknown | 9 (3) | 0 (0) | 5 (2) |
Days between first and second vaccine doses (median (IQR)) | |||
- Pfizer | 77 (21–150) | 77 (21–100) | 76 (22–91) |
- AstraZeneca | 77 (25–144) | 77 (35–102) | 77 (27–135) |
PCR proven prior Covid-19 infection (Number(%)) | 20 (8) | 14 (7) | 5 (2) |
Samples after 1st vaccine dose (Number(%)) | 234 (90) | 180 (86) | 152 (73) |
- Days after vaccination (median (IQR)) | 30 (18–88) | 28 (14–75) | 38 (21–118) |
Samples after 2nd vaccine dose (Number(%)) | 236 (91) | 185 (89) | 201 (90) |
- Days after vaccination (median (IQR)) | 30 (12–119) | 30 (11–94) | 33 (19–75) |
S antibody titre after first vaccine dose (IU) | 7450 (2940–19,457) | 556 (189–3936) | 1388 (157–11,714) |
- Number(%) positive | 189–234 (81) | 61/180 (34) | 69/152 (45) |
S antibody titre after second vaccine dose (IU) | 30,807 (26593–31,914) | 4285 (295–26,230) | 18,673 (1127–30,470) |
- Number(%) positive | 227/236 (96) | 104/185 (56) | 140/201 (70) |